A study of CAR-T therapy for CD20+ blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of CAR-T therapy designed to target and kill CD20-positive cancer cells in people with blood cancers like B-cell lymphoma or lymphocytic leukemia. It is an early study to see if this approach is safe and works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a CD20+ blood cancer, like B-cell lymphoma or lymphocytic leukemia, and have already had standard treatments for it.
- You are healthy enough to be up and about (ECOG score 0 or 1).
- You have not had CAR-T or other gene-modified T cell therapy in the last 6 months.
- You do not have serious infections, HIV, active hepatitis B/C, or other major uncontrolled health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD20 and CD19) on cancer cells. It is for people with B-cell cancers like lymphoma or leukemia that have come back or not responded to other treatments.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
This trial tests a new treatment that uses a virus to make your own immune cells attack two targets on cancer cells. It is for people with B-cell blood cancers that have come back or not responded to other treatments.
This study tests a new type of CAR T cell therapy that targets the CD20 protein on B-cell lymphoma cells. It is for people with certain types of B-cell lymphoma that have not responded to at least two previous treatments and who cannot use or have already tried the approved CD19 CAR T therapy.
Hear when a new Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.